CK Life Sciences (HKG:0775) subsidiary Sealbond sold the entire stake in Canadian company Pharmagesic to Nasdaq-listed Virios Therapeutics for $100 million, according to a Monday filing with the Hong Kong Stock Exchange.
Virios will pay for the acquisition through the issuance of 211,383 shares of purchaser common stock and 2,108.3854 shares of non-voting purchaser preferred stock, the filing said.
One purchase preferred stock will be convertible into 10,000 shares of purchaser common stock, according to the filing.
Conjoint, another CK Life Sciences subsidiary, lent HK$19.5 million to Virios, the filing said.
Both transactions will result in the business combination of Wex Pharmaceuticals, a Canada-based subsidiary of Pharmagesic, the filing said.
Shares rise 8% during Tuesday's afternoon trading.
Price (HKD): $0.55, Change: $+0.030, Percent Change: +5.77%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。